R&D Systems Inc. Tocris Bioscience Boston Biochem

Iressa

Cat. No. 3000

Iressa C22H24ClFN4O3 [184475-35-2]

Price and Availability

For Iressa pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Special Conditions

No more than 1 g per individual per year to be sold without prior permission from the license holder.

Alternative Names: Gefitinib, ZD 1839

Chemical Name: N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine

Biological Activity

Orally active, selective inhibitor of EGFR tyrosine kinase (IC50 = 23 - 79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts.

Licensing Information

Sold for research purposes only under agreement from AstraZeneca

Technical Data

M.Wt:
446.9
Formula:
C22H24ClFN4O3
Solubility:
Soluble to 100 mM in DMSO and to 10 mM in ethanol
Purity:
>98 %
Storage:
Store at RT
CAS No:
184475-35-2

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Other Information

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet

References

Baselga et al (2000) ZD1839 ('Iressa'), as an anticancer agent. Drugs 60 (Suppl. 1) 33. PMID: 11129170.

Ciardiello et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin.Cancer Res. 6 2053. PMID: 10815932.

McKillop et al (2005) Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol.Cancer Ther. 4 641. PMID: 15827338.

If you know of a relevant citation for this product please let us know.

Keywords: Iressa, supplier, Orally, active, selective, EGFR, inhibitors, Epidermal, Growth, Factors, Receptors, ErbB, Her, Receptor, Tyrosine, Kinases, RTKs, AstraZeneca, ZD1839

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Guide

Highlights over 350 products for cancer research. Request a copy or view PDF today.

divider line

Kinases Product Listing

Kinases Product Listing

Highlights over 350 products for kinase research. Request a copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Some of the most potent
kinase inhibitors all on one plate

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

divider line

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

Schizophrenia Poster

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.

divider line

New Product Guide

NPG

Highlights over 130 new products added in the second half of 2013. Request a copy or view PDF today.

divider line

New Products in this Area

PLX 647 dihydrochloride

Potent dual Fms/KIT inhibitor

BMS 599626 dihydrochloride

Potent, selective EGFR and ErbB2 inhibitor

Cyclotraxin B

TrkB receptor antagonist

Sign-up for new product e-alerts
divider line

Tocris Events

Meet your representative

R&D Symposium 2014

Molecular Mechanisms in Signal Transduction

July 15, 2014

Cambridge, UK